Hims and Hers Health Inc vs Marvell Technology Inc — how do they compare? Hims and Hers Health Inc trades at $30.34 (market cap $7.12B), while Marvell Technology Inc trades at $222.39 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 26.8× Hims and Hers Health Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | MRVL | |
|---|---|---|
Market Cap | $7.12B | $190.56B |
Sector | Health | Technology |
52-Week High | $62.76 | $316.43 |
52-Week Low | $14.52 | $62.31 |
Enterprise Value | $7.82B | $191.99B |
Dividend Yield | — | 0.11% |
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.
The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.
Marvell Technology (MRVL) trades at $221.15, up 6.04% today, reflecting strong momentum amid AI-driven optimism. The stock exhibits a bullish technical signal with moving averages supporting the uptrend, while recent earnings beats and a consensus analyst price target of $275.68 highlight fundamental strength. Key developments include partnerships with NVIDIA and Microsoft's Maia 300 AI accelerator, positioning MRVL for growth in data center and networking segments.
Outlook remains positive with AI infrastructure expansion driving revenue projections to $8.7B in 2026, though high valuation ratios (P/E 72.96) and supply chain risks warrant caution. Net income turned profitable in 2026 forecasts, but competitive pressures and market volatility pose challenges. Analyst consensus is strongly bullish with 82% buy ratings, suggesting upside potential if execution aligns with growth expectations.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →